Fundraising FoxInterMune
Unicorn exit · $8.3Bacquired by Roche3 known investors
Find your way into InterMune
Sign up to find every way you can get introduced to InterMune
- Your email: who you already know at InterMune, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the InterMune team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Acquired by Roche August 2014 · $8.3B ($74.00 per share, all-cash, ~$8.3 billion total) · source ↗
InterMune was a Brisbane, California biotechnology company focused on pulmonology and fibrotic diseases, best known for developing pirfenidone (Esbriet) to treat idiopathic pulmonary fibrosis.
Founders & leadership
Investors · 3
How we know: Ridgeback Capital's portfolio page · Not right? Tell us
How we know: Sanderling Ventures's portfolio page · Not right? Tell us
How we know: Sofinnova Ventures's portfolio page · the VCSheet dataset · Not right? Tell us
Founder mafia
2 people who came through InterMune went on to found or lead other companies.
Frequently asked questions
- What does InterMune do?
- InterMune was a Brisbane, California biotechnology company focused on pulmonology and fibrotic diseases, best known for developing pirfenidone (Esbriet) to treat idiopathic pulmonary fibrosis.
- Who are InterMune's investors?
- InterMune's investors include Ridgeback Capital, Sanderling Ventures, Sofinnova Ventures.
- Who acquired InterMune?
- InterMune was acquired by Roche.